mitoxantrone has been researched along with Graft vs Host Disease in 15 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ten patients with acute leukemia (AL) in early relapse after allo-BMT were treated with a modified MEC (mitoxantrone, etoposide and Ara-C) regimen followed by donor PBPC collected after mobilization with G-CSF." | 3.70 | Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. ( Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, A; Malcovati, L; Martinelli, G; Pagnucco, G; Salvaneschi, L, 1999) |
| "To investigate the efficacy and safety of MA (mitoxantrone and cytarabine) regimen chemotherapy combined with granulocyte-colony stimulating factor (G-CSF)-mobilized family related HLA-haploidentical donor peripheral blood hematopoietic stem cell (G-PBHSC) infusion for the treatment of acute myeloid leukemia (AML) patients aged over 80 years." | 1.42 | [Clinical Analysis of 4 AML Patients Aged Over 80 Years Treated with Chemotherapy Combined with Haploidentical Hematopoietic Stem Cell Infusion]. ( Hu, HL; Huang, YJ; Li, J; Liu, J; Sun, WJ; Xi, XQ; Zhao, HX, 2015) |
| "This report describes a patient with Ollier disease and AML and may offer a clue into the genetic pathogenesis of these disorders." | 1.35 | Acute myelogenous leukemia associated with Ollier disease. ( Martin, PL; McLean, TW; White, MS, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (33.33) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Boga, C | 1 |
| Sisli, SN | 1 |
| Bahar, AR | 1 |
| Tamer, Y | 1 |
| Kasar, M | 1 |
| Bascil, S | 1 |
| Ozdogu, H | 1 |
| Asma, S | 1 |
| Demiroglu, YZ | 1 |
| Yeral, M | 1 |
| Liu, J | 1 |
| Sun, WJ | 1 |
| Zhao, HX | 1 |
| Li, J | 1 |
| Huang, YJ | 1 |
| Xi, XQ | 1 |
| Hu, HL | 1 |
| Machaczka, M | 1 |
| Nahi, H | 1 |
| Karbach, H | 1 |
| Klimkowska, M | 1 |
| Hägglund, H | 1 |
| Cho, SF | 1 |
| Liu, TC | 1 |
| Chang, CS | 1 |
| Wernstedt, P | 1 |
| Brune, M | 1 |
| Andersson, PO | 1 |
| Gustavsson, B | 1 |
| Stockelberg, D | 1 |
| Wadenvik, H | 1 |
| Kang, SP | 1 |
| Liu, Db | 1 |
| Qureshi, A | 1 |
| Seiter, K | 1 |
| White, MS | 1 |
| Martin, PL | 1 |
| McLean, TW | 1 |
| Huang, XJ | 1 |
| Liu, DH | 1 |
| Liu, KY | 1 |
| Xu, LP | 1 |
| Chen, H | 1 |
| Han, W | 1 |
| Michel, G | 1 |
| Leverger, G | 1 |
| Leblanc, T | 1 |
| Nelken, B | 1 |
| Baruchel, A | 1 |
| Landman-Parker, J | 1 |
| Thuret, I | 1 |
| Bergeron, C | 1 |
| Bordigoni, P | 1 |
| Esperou-Bourdeau, H | 1 |
| Perel, Y | 1 |
| Vannier, JP | 1 |
| Schaison, G | 1 |
| Kuga, T | 1 |
| Kohda, K | 1 |
| Hirayama, Y | 1 |
| Matsumoto, S | 1 |
| Nakazawa, O | 1 |
| Ando, M | 1 |
| Ezoe, A | 1 |
| Nobuoka, A | 1 |
| Mochizuki, C | 1 |
| Nagler, A | 1 |
| Soni, S | 1 |
| Samuel, S | 1 |
| Or, R | 1 |
| Alessandrino, EP | 1 |
| Bernasconi, P | 1 |
| Caldera, D | 1 |
| Colombo, A | 1 |
| Malcovati, L | 1 |
| Martinelli, G | 1 |
| Bonfichi, M | 1 |
| Pagnucco, G | 1 |
| Salvaneschi, L | 1 |
| Bernasconi, C | 1 |
| Hambach, L | 1 |
| Eder, M | 1 |
| Dammann, E | 1 |
| Battmer, K | 1 |
| Stucki, A | 1 |
| Heil, G | 1 |
| Ganser, A | 1 |
| Hertenstein, B | 1 |
| Suminoe, A | 1 |
| Matsuzaki, A | 1 |
| Hattori, H | 1 |
| Ishii, S | 1 |
| Hara, T | 1 |
| Johnson, PR | 1 |
| Yin, JA | 1 |
| Drayson, MT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2[NCT00149162] | Phase 3 | 580 participants (Anticipated) | Interventional | 2005-03-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for mitoxantrone and Graft vs Host Disease
| Article | Year |
|---|---|
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation | 2001 |
Unrelated cord blood transplantation for an infant with chemotherapy-resistant progressive Langerhans cell histiocytosis.
Topics: Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Drug Resi | 2001 |
3 trials available for mitoxantrone and Graft vs Host Disease
| Article | Year |
|---|---|
Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Child; Combined Modality Therapy; Cytarabine; | 2007 |
Allogeneic bone marrow transplantation vs aggressive post-remission chemotherapy for children with acute myeloid leukemia in first complete remission. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation | 1996 |
Engraftment following mitoxantrone (Mito) based conditioning for allogeneic bone marrow transplantation (allo-BMT).
Topics: Adolescent; Adult; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Comb | 1998 |
10 other studies available for mitoxantrone and Graft vs Host Disease
| Article | Year |
|---|---|
Assessment of Stem Cell Transplant Eligibility in Recipients with Oral Foci of Infection: Appropriate Conditioning Regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Graft vs Host Disease; H | 2023 |
[Clinical Analysis of 4 AML Patients Aged Over 80 Years Treated with Chemotherapy Combined with Haploidentical Hematopoietic Stem Cell Infusion].
Topics: Aged, 80 and over; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Female; Graft vs Ho | 2015 |
Successful treatment of recurrent malignancy-associated hemophagocytic lymphohistiocytosis with a modified HLH-94 immunochemotherapy and allogeneic stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabine; Dexame | 2012 |
Isolated central nervous system relapse presenting as myeloid sarcoma of acute myeloid leukemia after allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cerebellopontine Angle; Combined Modality The | 2013 |
Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
Topics: Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; | 2002 |
Presentation of extramedullary acute myelogenous leukemia as bilateral testicular masses: response to non-myeloablative allogeneic transplantation.
Topics: Aged; Bone Marrow Transplantation; Combined Modality Therapy; Cytarabine; Graft vs Host Disease; Hum | 2004 |
Acute myelogenous leukemia associated with Ollier disease.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2008 |
Pulmonary veno-occlusive disease accompanied by microangiopathic hemolytic anemia 1 year after a second bone marrow transplantation for acute lymphoblastic leukemia.
Topics: Adolescent; Adrenal Cortex Hormones; Anemia, Hemolytic; Anti-Infective Agents; Antineoplastic Combin | 1996 |
Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Combined | 1999 |
Thrombotic thrombocytopenic purpura following allogeneic bone marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Cyclophosphamide; Epilepsy, Tonic-Clonic; Fever; Graft vs Host D | 1991 |